MET and gastric cancer: Furthermore, hepatocyte growth factor (rilotumumab, a fully human IgG2 monoclonal antibody against HGF), hepatocyte growth factor receptor (onartuzumab, humanized monoclonal antibody directed against HGFR), and EGFR (cetuximab, an anti-EGFR monoclonal antibody and a nimotuzumab that is a humanized monoclonal IgG1 antibody to EGFR), are also the targets of treatment in GC[101-104].